{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:17Z","timestamp":1769126417561,"version":"3.49.0"},"reference-count":8,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijdvl.ijdvl_232_18","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T11:45:44Z","timestamp":1538567144000},"page":"745","source":"Crossref","is-referenced-by-count":9,"title":["Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa"],"prefix":"10.25259","volume":"84","author":[{"given":"Sharmila","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.242673-1","first-page":"1235","article-title":"Hidradenitis suppurativa CMAJ","author":"Sibbald","year":"2015","journal-title":""},{"key":"key-10.4103\/0378-6323.242673-2","first-page":"114","article-title":"What is hidradenitis suppurativa?","author":"Lee","year":"2017","journal-title":"Can Fam Physician"},{"key":"key-10.4103\/0378-6323.242673-3","first-page":"1","article-title":"Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197","author":"Bandyopadhyay","year":"2015","journal-title":"Biosimilars"},{"key":"key-10.4103\/0378-6323.242673-4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/1756-185X.12711","article-title":"A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis","author":"Jani","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"key-10.4103\/0378-6323.242673-5","first-page":"1","article-title":"Adalimumab (Humira) for the treatment of hidradenitis suppurativa","author":"Gupta","year":"2016","journal-title":"Skin Therapy Lett"},{"key":"key-10.4103\/0378-6323.242673-6","first-page":"580","article-title":"Long-term successful adalimumab therapy in severe hidradenitis suppurativa","author":"Blanco","year":"2009","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.242673-7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.242673-8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2340\/00015555-2069","article-title":"Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis","author":"Chiu","year":"2015","journal-title":"Acta Derm Venereol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:43:28Z","timestamp":1611917008000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/low-dose-adalimumab-biosimilar-zrc-3197-in-the-treatment-of-hidradenitis-suppurativa\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"alternative-id":["242673"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_232_18","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}